课题基金 / 基金详情

GNRH ANALOG TOXINS FOR TARGETED GONADOTROPH ABLATION

GNRH ANALOG TOXINS FOR TARGETED GONADOTROPH ABLATION
用于靶向性促性腺激素消融的 GNRH 类似毒素
批准号:
6172694
负责人:
L MICHAEL GLODE
金额:
$25.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-08-01 至 2002-09-30

项目摘要

项目成果

L MICHAEL GLODE的其他基金

相关文献

中文摘要
翻译
激素敏感型癌症是美国老龄化人口发病率和死亡率的主要原因。乳腺癌和前列腺癌都可以用性类固醇拮抗剂治疗,但成本和此类化合物的突变逃逸使永久性阉割成为更可取的治疗方式。促性腺激素释放激素超激动剂被用来对患有这种癌症和其他激素依赖性异常的人进行化学去势。这种治疗的一个主要缺点是,GnRH超级激动剂必须在患者的一生中持续服用才能产生欲望效果。Gonex Inc.拥有获得许可的技术,可以开发在一次给药后可能永久阻止性腺功能的化合物。这项技术是基于有毒蛋白质与GnRH超级激动剂的结合,GnRH超级激动剂将特异性地将毒素输送到脑下垂体前叶的促性腺激素细胞。然后毒素破坏促性腺激素细胞,导致性腺功能停止。在这个第二阶段的应用中,我们建议对三种不同的GnRH毒素结合物进行评估,目的是确定最有效地消除性腺功能的毒素和给药方式。其具体目的是:1)比较三种不同GnRH-毒素结合物在绵羊垂体前叶细胞中的内化率;2)评估不同剂量的GnRH-毒素结合物在绵羊团注后的疗效和毒性;以及3)确定持续滴注GnRH-毒素结合物是否比团注更有效地消除促性腺功能。在这些研究结束时,我们将选择一种将被带入毒理学和药理学研究的先导化合物,为提交INDA做准备。拟议的商业应用:使用促性腺激素释放激素类似物-毒素结合物可以提供一种单次注射的方法永久抑制促性腺激素的分泌。因此,这些化合物将为目前治疗类固醇依赖型癌症的方法提供一种更好的替代方案。
英文摘要
Hormonally responsive cancers are a major cause of morbidity and mortality in the aging population in the Unites States. Both breast and prostate cancer can be treated by sex steroid antagonists, but cost and mutational escape from such compounds make permanent castration a more desirable treatment modality. GnRH superagonists are used to "chemically castrate" individuals affected with such cancers and other hormonally dependent abnormalities. A major disadvantage of this treatment is that the GnRH superagonists must be administered continuously for life of the patient to produce the desire effect. Gonex Inc. has licensed technology to pursue development of compounds that after a single administration have the potential to prevent gonadal function permanently. The technology is based on the conjugation of a toxic protein to a GnRH superagonist that will specifically deliver the toxin to gonadotrophs in the anterior pituitary gland. The toxin then destroys the gonadotrophs resulting in cessation of gonadal function. In this Phase II application, we propose experiments to evaluate three different GnRH toxin conjugates with the goal of identifying the toxin and mode of administration that is most efficacious for eliminating gonadal function. The specific aims are to: 1) To compare the rate of internalization of three different GnRH-toxin conjugates in ovine anterior pituitary cells; 2) To evaluate the efficacy and toxicity of different doses of GnRH-toxin conjugates after bolus administration of rams; and 3) To determine if continuous infusion of GnRH-toxin conjugates eliminates gonadotroph function more efficiently than bolus administration. At the end of these studies, we will select a lead compound that will be taken forward into toxicological and pharmacological studies in preparation for filing of an INDA. PROPOSED COMMERCIAL APPLICATION: The use of GnRH analog-toxin conjugates may provide a single-shot approach to permanent inhibition of gonadotropin secretion. As such, these compounds would provide a superior alternative to currently available methods for treating steroid-dependent cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development and testing of a silibin-containing sunscreen
  • 批准号:
    7210773
  • 项目类别:
  • 资助金额:
    $10.82万
  • 财政年份:
    2007
  • 负责人:
    L MICHAEL GLODE
  • 依托单位:
Cytotoxic Gonadotropin Releasing Hormone Derivatives
  • 批准号:
    6479651
  • 项目类别:
  • 资助金额:
    $24.72万
  • 财政年份:
    2002
  • 负责人:
    L MICHAEL GLODE
  • 依托单位:
Cytotoxic Gonadotropin Releasing Hormone Derivatives
  • 批准号:
    6625863
  • 项目类别:
  • 资助金额:
    $24.71万
  • 财政年份:
    2002
  • 负责人:
    L MICHAEL GLODE
  • 依托单位:
MOLECULAR MARKERS FOR PROSTATE CANCER DETECTION
  • 批准号:
    2828530
  • 项目类别:
  • 资助金额:
    $11.33万
  • 财政年份:
    1999
  • 负责人:
    L MICHAEL GLODE
  • 依托单位: